Trial Profile

Window of Opportunity Trial of Olaparib and Durvalumab (MEDI4736) Before Standard Neoadjuvant Chemotherapy for Stage II/III Triple Negative or Low ER+ Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Olaparib (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin
Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms MEDIOLA

Most Recent Events

17 Apr 2025 Planned End Date changed from 30 Dec 2022 to 31 Dec 2025.
17 Apr 2025 Planned primary completion date changed from 30 Dec 2021 to 31 Dec 2025.
18 Jun 2021 Planned End Date changed from 30 Apr 2020 to 30 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com